PANTANO, FRANCESCO
 Distribuzione geografica
Continente #
AS - Asia 6.193
NA - Nord America 1.478
EU - Europa 617
SA - Sud America 276
AF - Africa 28
OC - Oceania 13
AN - Antartide 1
Totale 8.606
Nazione #
SG - Singapore 4.661
US - Stati Uniti d'America 1.394
CN - Cina 734
HK - Hong Kong 519
BR - Brasile 202
IT - Italia 172
GB - Regno Unito 132
VN - Vietnam 129
DE - Germania 82
CA - Canada 45
IN - India 45
NL - Olanda 42
AR - Argentina 37
MX - Messico 28
FI - Finlandia 24
JP - Giappone 22
FR - Francia 21
CZ - Repubblica Ceca 20
ID - Indonesia 20
TR - Turchia 18
RU - Federazione Russa 16
ES - Italia 15
PL - Polonia 14
ZA - Sudafrica 14
UA - Ucraina 13
AU - Australia 12
SE - Svezia 12
BD - Bangladesh 11
AT - Austria 10
EC - Ecuador 10
EE - Estonia 9
KR - Corea 7
CO - Colombia 6
LT - Lituania 6
CL - Cile 5
PY - Paraguay 5
VE - Venezuela 5
RO - Romania 4
SA - Arabia Saudita 4
BE - Belgio 3
DK - Danimarca 3
GR - Grecia 3
PE - Perù 3
PT - Portogallo 3
RS - Serbia 3
TN - Tunisia 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
CH - Svizzera 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
KZ - Kazakistan 2
LV - Lettonia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DZ - Algeria 1
EG - Egitto 1
GP - Guadalupe 1
GT - Guatemala 1
HT - Haiti 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
LB - Libano 1
LY - Libia 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MS - Montserrat 1
MW - Malawi 1
MY - Malesia 1
NP - Nepal 1
PH - Filippine 1
PK - Pakistan 1
PR - Porto Rico 1
SI - Slovenia 1
SN - Senegal 1
TH - Thailandia 1
TO - Tonga 1
TW - Taiwan 1
YE - Yemen 1
Totale 8.606
Città #
Hong Kong 518
Singapore 468
Ashburn 354
Hefei 330
Dallas 227
Boardman 172
Beijing 157
London 116
Shanghai 113
Los Angeles 58
Ho Chi Minh City 46
Munich 40
Rome 40
San Francisco 40
Council Bluffs 30
Amsterdam 26
Hanoi 26
Santa Clara 25
New York 24
Pune 24
São Paulo 24
Toronto 21
Brooklyn 20
Brno 19
Mexico City 19
Seattle 17
Redmond 16
Montreal 15
Helsinki 14
Washington 14
Chicago 12
Tokyo 12
Warsaw 11
Haiphong 10
Stockholm 10
Turku 10
Xi'an 9
Boston 8
Milan 8
Ankara 7
Biên Hòa 7
Canberra 6
Johannesburg 6
Campinas 5
Charlotte 5
Chennai 5
Denver 5
Hyderabad 5
Las Vegas 5
Melbourne 5
Naples 5
Paris 5
Phoenix 5
Rio de Janeiro 5
Yeonsu-gu 5
Atlanta 4
Bauru 4
Buenos Aires 4
Curitiba 4
Ha Long 4
Miami 4
New Delhi 4
Ninh Bình 4
Oklahoma City 4
Padova 4
Ribeirão Preto 4
Riyadh 4
Sona 4
Vienna 4
West Jordan 4
Asunción 3
Athens 3
Belo Horizonte 3
Camaçari 3
Capaccio 3
Copenhagen 3
Durham 3
Jakarta 3
Manchester 3
Montesilvano Marina 3
Moscow 3
Ningbo 3
Pescara 3
Porto 3
Porto Alegre 3
Quito 3
San Jose 3
San José 3
Tashkent 3
Anyang 2
Astana 2
Baku 2
Boca Raton 2
Buffalo 2
Bắc Giang 2
Caluire-et-Cuire 2
Campina Grande 2
Cape Town 2
Catanduva 2
Catania 2
Totale 3.328
Nome #
1065P Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC 255
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference? 230
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases 223
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence 214
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment 213
Abstract 486: MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes 213
Designing a broad-spectrum integrative approach for cancer prevention and treatment 213
A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation 205
Artificial Intelligence in Detection, Management, and Prognosis of Bone Metastasis: A Systematic Review 200
Premetastatic niche: ready for new therapeutic interventions? 198
NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population 176
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 176
BOMB trial: First results of stereotactic radiotherapy to primary breast tumor in metastatic breast cancer patients 130
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 129
Concurrent Use of Abemaciclib and Radiotherapy in Metastatic Breast Cancer Patients: A Single-Center Experience 118
'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer 117
Anterior and posterior vaginal myomectomy: A new surgical technique 113
Clinical outcomes among major breast cancer subtypes after neoadjuvant chemotherapy: Impact on breast cancer recurrence and survival 107
Subaxillary Replacement Flap Compared with the Round Block Displacement Technique in Oncoplastic Breast Conserving Surgery: Functional Outcomes of a Feasible One Stage Reconstruction 107
Biological effects of cabozantinib on bone microenvironment 103
A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twins 100
Abstract P5-04-13: Antibody-based therapy targeting integrin a5 is an effective strategy to treat experimental breast cancer bone metastasis 100
Preoperative Ultrasound-guided Sub-areolar Biopsy in Predicting Occult Nipple Involvement in Breast Cancer Patients: Proposal for a Methodological Approach 99
Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series 98
Heterogeneous risk profiles among B3 breast lesions of uncertain malignant potential 97
Biological effects of cabozantinib on osteosarcoma-bone microenvironment model 97
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis 96
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 96
Body Mass Index and Impaired Fasting Blood Glucose as Predictive Factors of Efficacy in Cetuximab-Based Colorectal Cancer Treatment 96
Different Levels of Alkaline Phospatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions 96
Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw 95
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions 95
Antitumor effect of cabozantinib in bone metastatic models of renal cell carcinoma 95
Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. 93
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 91
Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. 91
Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs). 89
Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge 68
A Nanostring gene expression approach identifies aggressive clinical behavior related genes in dedifferentiated liposarcoma 64
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 55
Molecular prognostic factors in patients with pancreatic cancer 54
New targets, new drugs for metastatic bone pain: a new philosophy 52
Role of c-mesenchymal-epithelial transition pathway in gastric cancer 51
MicroRNAs and bone metastasis: a new challenge 47
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients 44
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models 42
Denosumab for cancer-related bone loss 41
MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients 40
Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis 38
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 38
New Technologies to Study the Interplay between Cancer Stem Cells and the Immune System 38
Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence 37
Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone 37
Network approach in liquidomics landscape 37
Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs) 36
Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms 36
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7) 35
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 35
The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients 34
Neutrophil-to-lymphocyte ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and outcomes with nivolumab in pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study 34
Epidemiologia e caratteristiche delle metastasi ossee 34
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma 34
CETUXIMAB: From bench to bedside 33
Targeting bone metastases starting from the preneoplastic niche: home sweet home 32
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 32
Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part I: Classification, diagnosis and staging 32
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives 32
Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients 31
Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment 31
Interleukin 1ss-511T gene (IL1ss) polymorphism is correlated with gastric cancer in the Caucasian population: Results from a meta-analysis 31
Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. 31
Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study 31
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma 31
Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in advanced leiomyosarcoma and angiosarcoma 31
Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation 31
The Synergistic Effect of Everolimus and Chloroquine on Endothelial Cell Number Reduction Is Paralleled by Increased Apoptosis and Reduced Autophagy Occurrence 30
Tissue invasion and metastasis: Molecular, biological and clinical perspectives. 30
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial 30
Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients 30
Oncologia 30
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature 29
Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis 29
Olaratumab: PDGFR-alpha inhibition as a novel tool in the treatment of advanced soft tissue sarcomas 29
Regression of papillary thyroid cancer during nivolumab for renal cell cancer 29
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 29
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials 29
Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer 28
Bone Health in Cancer Patients 28
The role of bone microenvironment, vitamin D and calcium 28
Monoclonal antibodies 28
Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions 28
miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes 28
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis 27
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker? 27
Targeted therapies for bone metastases 27
TUMORI NEUROENDOCRINI 27
Deregulation of dicer and mir-155 expression in liposarcoma 27
Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives 27
Integrin alpha-5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions 27
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 27
Totale 7.242
Categoria #
all - tutte 70.388
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.388


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022328 0 0 9 1 89 4 8 1 12 1 3 200
2022/202363 2 1 0 1 4 3 7 15 1 3 23 3
2023/2024508 16 49 30 31 50 224 6 20 6 24 16 36
2024/20255.748 76 92 206 49 39 137 115 31 491 456 1.794 2.262
2025/20262.095 484 226 397 511 249 228 0 0 0 0 0 0
Totale 8.742